DOCSLIB.ORG

V21 MTG 0033 List of Particip

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
V21 MTG 0033 List of Particip THE FIRST WHO INTEGRATED MEETING ON DEVELOPMENT AND CLINICAL TRIALS OF INFLUENZA VACCINES THAT INDUCE BROADLY PROTECTIVE AND LONG-LASTING IMMUNE RESPONSES Baptist University, Hong Kong 24 – 26 January 2013 LIST OF PARTICIPANTS Dr Akira Ainai, Emeritus Member, National Institute of Infectious Diseases, Tokyo, Japan Dr Christopher Ambrose, Senior Director, Medical Affairs, MedImmune, Gaithersburg, United States of America Professor Filippo Ansaldi, Health Sciences, University of Genoa and Hygiene Unit, Genoa, Italy Dr Robert L. Atmar, Associate Professor, Department of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, United States of America Dr Emma Ball, CSL Limited A.C.N., Parkville, Victoria, Australia Dr Pamuk Bilsel, FluGen Inc., Madison, United States of America Mr Albert Chan, President, Hong Kong Baptist University, Hong Kong, China Dr Paul Chan, Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China Dr Marta Coehlo Nunes, Respiratory and Meningeal Pathogens Research Unit, Wits University, Johannesburg, South Africa Dr Ben Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China Dr Manon Cox, President and CEO, Protein Sciences Corporation, Meridien, United States of America Professor Rebecca Cox, Influenza Centre, The Gade Institute, University of Bergen, Bergen, 5021 Norway Dr Giuseppe Del Giudice, Global Head Translation Medicine, Novartis Vaccines and Diagnostics S.p.A, Divisione Biologici et Farmaceutici, Novartis Vaccines, Siena, Italy Dr Carlos Diaz Granados, Clinical Team Leader, Director Clinical Development, Sanofi Pasteur, United States of America Dr Katherine Donegan, Medicines and Healthcare products Regulatory Agency, London, United Kingdom Dr Emelia Dwiyanti Wibowo, Head of Production, Indonesia Dr Othmar Engelhardt, Principal Scientist, National Institute for Biological Standards and Control, Health Protection Agency, Potters Bar, Hertfordshire, United Kingdom Professor Janet Englund, Professor at University of Washington, Infectious Disease Program, University of Washington, Seattle, United States of America Dr Marina Erofeeva, Head of the Laboratory of Trials of Novel Remedies for Antiviral Protection Research, Institute of Influenza, St Petersburg, Russia Dr Jose Esparza, Senior Advisor on HIV Vaccines, HIV, TB & Reproductive Health, Global Health Program, The Bill & Melinda Gates Foundation, Seattle, Washington D.C, United States of America Dr Susanna Esposito, Department of Pathophysiology and Transplantation, Università degli Studi di Milan, Milano, Italy Professor Sarah Gilbert, Professor of Vaccinology, The Jenner Institute, Oxford, United Kingdom Dr Marc Girard, Consultant, Lyon, France Dr Hugo Gomes da Silva, Global Medical Lead, HIV & Influenza, GSK, Wavre, Belgium Ms Tanya Gottlieb, Business Development, Biond Vax Pharmaceuticals Ltd, Nes Ziona, Israel Dr Yi Guan, The Univerisity of Hong Kong, Hong Kong, China Professor Frederick Hayden, Influenza Research Coordinator, International activities-Science Funding, The Wellcome Trust, London, United Kingdom Dr Guillermo Herrera-Taracena, GMA Leader for Infectious Diseases and Vaccines, Johnson & Johnson, New Brunswick, United States of America Dr Baoying Huang, Institute for Viral Disease Control and Prevention, Xuan Wu Qu, China Dr Dr Dr Baoying Hunag, Institute for Viral Disease Control and Prevention, Xuan-WU Qu, China Dr Robert Huebner, Acting Director - Influenza Division, Biomedical Advanced Research & Development Authority (BARDA), US Department of Health and Human Services (HHS), Washington, United States of America Dr David Hui, Director, Stanley Ho Center for Emerging Infectious Diseases, Hong Kong, China Professor Margaret IP, Department of Microbiology, The Chinese University of Hong Kong, Hong Kong, China Dr Irina Isakova-Sivak, Department of Virology, Institute of Experimental Medicine, St. Petersburg, Russia Dr Mark Jit, Mathematical Modeller, Modelling and Economics Unit, Health Protection Agency, London, United Kingdom Dr Jacqueline M. Katz, Epidemiology and Prevention Branch, Influenza Division, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America Dr Anne Kelso, Director, WHO Collaborating Centre for Reference & Research on Influenza, Melbourne, Victoria, Australia Dr Soo In Kim, Green Cross Corporation, Gyeonggi-do, Republic of Korea Dr Otfried Kistner, Senior Director, Virology/Viral Vaccines, Biomedical Research Center, Baxter BioScience, Orth/Donau, Austria Dr Harry Kleanthous, Head, Discovery Research, North America, Sanofi Pasteur Biologics Co., Cambridge, United States of America Ms Janna Klein Bretler, Preparedness and Response Unit, Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM) Bilthoven, Netherlands Dr Florian Krammer, Department of Microbiology, Mount Sinai School of Medicine, New York, United States of America Professor Dominc Man-Kit Lam, Chairman, World Eye Organization, Hong Kong, China Dr Fong Lam, Baylor College of Medicine, Pediatric Crucial Care, Texas Children’s Hospital, Houston, Texas, United States of America Ms Nathalie Landry, Vice- President, Product Development, Research & Development, Medicago R & D Inc. Quebec, Canada Dr Vernon Lee, Adjunct Associate Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore Mr Bertrand Lepine, President Fab'entech, Fab'entech, Lyon, France Dr Xiaoyu Liu, Institute for Viral Disease Control and Prevention, China CDC, Beijing, China Dr Xiuhua Lu, Centers for Diseases Control and Prevention, Atlanta, United States of America Professor Arnold Monto, The Thomas Francis Jr. Professor, Epidemiology, The University of Michigan School of Public Health, Ann Arbor, United States of America Professor Antony E. Nelson, Professor, Department of Paediatrics - Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China Dr Kathleen Neuzil, Programme Leader Vaccine Access and Delivery (VAD) Program, Program for Appropriate Technology in Health, Seattle, United States of America Dr Huan H. Nguyen, Principal Investigator, International Vaccine Institute, Kwanak-gu, Seoul, Republic of Korea Professor Thu Van Nguyen, General Director, The Company for Vaccine and Biologicals Production No.1, National Institute of Hygiene and Epidemiology, Hanoi, Viet Nam Professor Angus Nicoll, Senior Expert, Influenza Coordination, European Centre for Disease Prevention and Control, Stockholm, Sweden Dr Hanna Nohynek, Academy Research Fellow, ARIVAC Coordinator, Vaccine Research, National Institute for Health and Welfare, Helsinki, Finland Dr Joerdis J. Ott, Consultant, Vevey, Switzerland Professor Malik Peiris, The University of Hong Kong, Hong Kong, China Dr Yuri Pervikov, Consultant, Geneva, Switzerland Professor Punnee Pitisuttithum, Clinical Infectious Disease Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand Dr Leo Poon, State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong, China Dr Alexander R Precioso, Medical Director, Clinical Trials, Clinical Trials Division, Instituto Butantan, São Paulo, Brazil Dr Paul Radspinner, President & CEO, FluGen Inc., Madison, United States of America Dr Eleanor Ramos, Chief Medical Officer, Theraclone Sciences, Seattle, United States of America Mr Bambang Heriyanto Rasbun, Production Manager, Bio Farma, Bandung, Indonesia Professor Gustaaf Rimmelzwaan, Department of Virology, Erasmus Medical Center (MC), Rotterdam, Netherlands Dr Theodore Ross, Associate Professor, Center for Vaccine Research, Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America Professor Li-Ruan, Professor of Department, Biotech Center for Viral Disease Emergency, Chinese Center for Disease Control and Prevention, Beijing, China Professor Larisa Rudenko, Head, Department of Virology, Institute of Experimental Medicine, St. Petersburg, Russia Dr Rachelle Salomon, Program Officer, Influenza SARS & Related Viral Respiratory Diseases Section, Respiratory Diseases Branch, National Institute of Allergy and Infectious Diseases (NIAID/NIH), Bethesda, United States of America Dr Sandrine Sampson, Sanofi Pasteur, Lyon, France Dr Vivek Shinde, GlaxoSmithKline Biologicals SA, Rixensart, Belgium Dr Kunihiko Shinna, Director Global Vaccine Business, Astellas Pharma Inc., Tokyo, Japan Dr Yuelong Shu, Director, WHO Collaborating Center for Reference and Research on Influenza, China Center for Disease Control and Prevention, Beijing, China Dr Mark Simmerman, Regional Director, Epidemiology, Sanofi Pasteur, Bangkok, Thailand Dr Marina Stukova, Research Institute of Influenza, St Petersburg, Russia Dr Kanta Subbarao, Senior Investigator, Laboratory of Infectious Diseases, NIAID, National Institutes of Health, Bethesda, United States of America Dr Masato Tashiro, Director, Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan Professor Alain Townsend, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom Dr Theodore F. Tsai, Sr. VP, Scientific Affairs, Novartis Vaccines, Cambridge, United States of America Dr Vadim Tsvetnitsky, Influenza Project Leader, Vaccine Development Global Program, PATH, Washington DC, United States of America Dr Sophie Valkenburg, The University of Hong Kong, Hong Kong, China Professor Timo Vesikari, Vaccine Research
Load more

Recommended publications
  • Vaccine Hesitancy
    WHY CHILDREN WORKSHOP ON IMMUNIZATIONS ARE NOT VACCINATED? VACCINE HESITANCY José Esparza MD, PhD - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA - Robert Koch Fellow, Robert Koch Institute, Berlin, Germany - Senior Advisor, Global Virus Network, Baltimore, MD, USA. Formerly: - Bill & Melinda Gates Foundation, Seattle, WA, USA - World Health Organization, Geneva, Switzerland The value of vaccination “The impact of vaccination on the health of the world’s people is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth” Stanley Plotkin (2013) VACCINES VAILABLE TO PROTECT AGAINST MORE DISEASES (US) BASIC VACCINES RECOMMENDED BY WHO For all: BCG, hepatitis B, polio, DTP, Hib, Pneumococcal (conjugated), rotavirus, measles, rubella, HPV. For certain regions: Japanese encephalitis, yellow fever, tick-borne encephalitis. For some high-risk populations: typhoid, cholera, meningococcal, hepatitis A, rabies. For certain immunization programs: mumps, influenza Vaccines save millions of lives annually, worldwide WHAT THE WORLD HAS ACHIEVED: 40 YEARS OF INCREASING REACH OF BASIC VACCINES “Bill Gates Chart” 17 M GAVI 5.6 M 4.2 M Today (ca 2015): <5% of children in GAVI countries fully immunised with the 11 WHO- recommended vaccines Seth Berkley (GAVI) The goal: 50% of children in GAVI countries fully immunised by 2020 Seth Berkley (GAVI) The current world immunization efforts are achieving: • Equity between high and low-income countries • Bringing the power of vaccines to even the world’s poorest countries • Reducing morbidity and mortality in developing countries • Eliminating and eradicating disease WHY CHILDREN ARE NOT VACCINATED? •Vaccines are not available •Deficient health care systems •Poverty •Vaccine hesitancy (reticencia a la vacunacion) VACCINE HESITANCE: WHO DEFINITION “Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination services.
    [Show full text]
  • Clinical Scholars Visit Amish Research Clinic in Lancaster County, PA by Patrick Brunner, MD Dr
    Spring 2018 Center for Clinical and Translational Science e- e-NewsletterNewsletter Center News James Krueger and Marina Caskey, Representing the Nussenzweig Lab Team, Honored at Translational Science 2018 Meeting By Hospital Leadership which fulfill the translation research Dr. James Krueger received paradigm of going from bench to the Association for Clinical and bedside, have been recognized by this Translational Science (ACTS) most prestigious national recognition. Distinguished Investigator Award for his It is well deserved!” Upon receiving the groundbreaking research on psoriasis at award, Dr. Krueger noted, “This award the Translational Science 2018 meeting would not have been possible without attended by more than 1,100 people in the support of many others associated Washington, DC in April. His research with the Rockefeller CTSA enterprise: has led to a fundamental change in my lab members, the nursing staff, the paradigm for understanding the all other support departments and, pathophysiology of the disorder, and of course, hundreds of patients who this in turn has led to the development directly tested progressively better drugs of a series of novel medications that that are now used to so effectively treat precisely modulate the immune system psoriasis.” and dramatically improve the therapy of the disorder. Each year, Clinical Research Forum sponsors a competition to identify Dr. Caskey Receiving “Top Ten” Award from the “Top Ten” Clinical Research Drs. Harry Selker and Herb Pardes studies reported in the previous year. commented that “The study reflects the The competition is intense and so it very best in translational science: the is a true tribute to the novelty and careful analysis of patient phenotypes; importance of the study led by Dr.
    [Show full text]
  • Strategies for Improving Influenza Immunization Rates Among Hard-To-Reach Populations
    Journal of Urban Health: Bulletin of the New York Academy of Medicine, Vol. 84, No. 4 doi:10.1007/s11524-007-9197-z * 2007 The New York Academy of Medicine For permissions, please e-mail: [email protected] Advance Access publication Strategies for Improving Influenza Immunization Rates among Hard-to-Reach Populations David Vlahov, Micaela H. Coady, Danielle C. Ompad, and Sandro Galea ABSTRACT Whereas considerable attention has been devoted to achieving high levels of influenza immunization, the importance of this issue is magnified by concern over pandemic influenza. Most recommendations for vaccine administration address high risk groups such as the elderly and those with chronic diseases, but coverage for hard- to-reach (HTR) populations has had less attention. HTR populations include minorities but also include other primarily urban groups such as undocumented immigrants, substance users, the homeless, and homebound elderly. Obstacles to the provision of immunization to HTR populations are present at the patient, provider, and structural levels. Strategies at the individual level for increasing immunization coverage include community-based educational campaigns to improve attitudes and increase motivation for receiving vaccine; at the provider level, education of providers to encourage immunizations, improving patient–provider interactions, broadening the provider base to include additional nurses and pharmacists, and adoption of standing orders for immunization administration; and at the structural level, promoting
    [Show full text]
  • OPTIONS X Programme
    Options X for the Control of Influenza | WELCOME MESSAGES BREAKTHROUGH INFLUENZA VACCINES TAKE LARGE DOSES OF INNOVATION Protecting people from the ever-changing threat of influenza takes unwavering commitment. That’s why we’re dedicated to developing advanced technologies and vaccines that can fight influenza as it evolves. We’re with you. ON THE FRONT LINETM BREAKTHROUGH INFLUENZA VACCINES TAKE LARGE DOSES OF INNOVATION CONTENT OPTIONS X SUPPORTERS ------------------- 4 OPTIONS X EXHIBITORS & COMMITTEES ------------------- 5 AWARD INFORMATION ------------------- 6 WELCOME MESSAGES ------------------- 7 SCHEDULE AT A GLANCE ------------------- 10 CONFERENCE INFORMATION ------------------- 11 SOCIAL PROGRAMME ------------------- 14 ABOUT SINGAPORE ------------------- 15 SUNTEC FLOORPLAN ------------------- 16 SCIENTIFIC COMMUNICATIONS ------------------- 17 PROGRAMME ------------------- 19 SPEAKERS ------------------- 31 SPONSORED SYMPOSIA ------------------- 39 ORAL PRESENTATION LISTINGS ------------------- 42 POSTER PRESENTATION LISTINGS ------------------- 51 ABSTRACTS POSTER DISPLAY LISTINGS ------------------- 54 SPONSOR AND EXHIBITOR LISTINGS ------------------- 80 EXHIBITION FLOORPLAN ------------------- 83 Protecting people from the ever-changing threat of NOTE ------------------- 84 influenza takes unwavering commitment. That’s why we’re dedicated to developing advanced technologies and vaccines that can fight influenza as it evolves. We’re with you. ON THE FRONT LINETM Options X for the Control of Influenza | OPTIONS X SUPPORTERS
    [Show full text]
  • Report on Global Surveillance of Epidemic-Prone Infectious Diseases, 2000
    Pan American Health Organization Regional Office of the World Health Organization PAHO/DPC/CD-V/243/03 Original: English Report: Workshop on Dengue Burden Studies (Washington, DC, 5-7 November 2002) Convened by The Pan American Health Organization The Rockefeller Foundation The Pediatric Dengue Vaccine Initiative Executive Summary Background Dengue fever (DF) and dengue hemorrhagic fever (DHF) are caused by the mosquito borne virus, dengue virus, of which there are four antigenically distinct serotypes. It is estimated that annually these viruses cause at least 20 million infections worldwide leading to some 24,000 deaths (WHO, http://www.who.int/health_topics/dengue/en/ ). The alarming rise in dengue hemorrhagic fever in the world today is illustrated most starkly by the chart below which represents data from the World Health Organization (WHO) showing the rise of DHF cases over the last four decades. Indeed the first two years of the new millennium has seen outbreak after outbreak of DHF not only in Southeast Asia where DHF has been seen for half a century, but also in many countries of South and Central America. REPORTED CASES OF DHF 600 ds 500 housan t 400 n d i e 300 200 r report e 100 numb 0 1955-1959 1960-1069 1970-1979 1980-1989 1990-1998 Source: WHO; adapted from http://www.who.int/health_topics/dengue/en/ While there is no doubt that severe dengue is spreading from countries in Southeast Asia to countries in the Pacific and in the Americas, there is also no doubt that many international efforts into the development of dengue vaccines have led to a number of promising vaccine candidates which may offer some solutions to the control of this disease.
    [Show full text]
  • 5Th Annual Short Course in Medical Virology Baltimore, MD August 5-11
    5th Annual Short Course in Medical Virology Baltimore, MD ǀ August 5-11, 2018 ǀ Program Locations: IHV ǀ Baltimore JH ǀ Baltimore NIH ǀ Bethesda Sunday, August 5 3:00 PM Hotel Check In 6:00-8:00 PM Short Course Opening Dinner at Diamond Tavern Monday, August 6 9:00-10:00 AM Shyam Kottilil, MD, PhD, Institute of Human Virology "Hepatitis C" 10:00-10:15 AM Coffee break 10:15- 11:15 AM Yutaka Tagaya, MD, PhD, Institute of Human Virology "Human T-cell leukemia virus-1, an exceptionally oncogenic retrovirus" 11:15-12:15 PM Robert Gallo, MD, Institute of Human Virology "Human Retroviruses: HTLV and HIV: an Overview” 12:15- 1:15 PM group picture & lunch 1:15-2:15 PM Jose Esparza, MD, PhD, Institute of Human Virology "Vaccines" 2:15-3:15 PM Alfredo Garzino-Demo, PhD, Institute of Human Virology "HIV Pathogenesis" 3:15-3:30 PM Coffee break 3:30- 4:30 PM Neil Constantine, PhD, Insitute of Human Virology "Laboratory diagnostics" Tuesday, August 7 8:15 AM Transportation to Johns Hopkins Bloomberg School of Public Health 9:00-10:00 AM Diane Griffin, PhD, MD, Johns Hopkins Bloomberg School of Public Health "Measles" 10:00-11:00 AM Ken Olson, PhD, Colorado State University "Arboviruses" 11:00-11:30 AM Break 11:30-12:30 AM Marcelo Jacobs-Lorena, PhD, Johns Hopkins Bloomberg School of Public Health Insectary Tour 12:30-1:30 PM Lunch 1:30-2:30 PM Transportation to IHV/ Coffee Break 2:30-4:30 PM GVN Short Course Partcipant's research presentations 4:30-5:30 PM Yuki Furuse, PhD, MD, Tohoku University, Japan New Emerging leader presentation: What can we do and what should we do during Ebola outbreak? Wednesday, August 8 9:00-10:00 AM Ab Osterhaus, DVM, PhD, University of Veterninary Medicine Hannover "One Health" 10:00-11:00 AM Stefan Sarafianos, PhD, Emory School of Medicine "Antiviral drug discovery" 11:30- 12:30 AM Robert Garry, PhD, Tulane University "Ebola and Lassa fever" 12:30-1:30 PM Lunch 1:30-2:30PM Konstantin Chumakov, FDA “Polio and other Enteroviruses” 2:30-3:30 PM Richard H.
    [Show full text]
  • José Esparza MD, Phd - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
    Vaccination: lost opportunities José Esparza MD, PhD - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. - Formerly at the World Health Organization (Geneva, Switzerland) and the Bill & Melinda Gates Foundation (Seattle, WA, USA). Outline • The public health value of vaccination • Different types of vaccine hesitancy • Some historical examples of vaccine introduction and impact • The case of dengue vaccines • Conclusions Ten Great Public Health Achievements of the 20th Century (in the US) 1. Vaccines 2. Motor vehicle safety 3. Workplace safety 4. Control of infectious diseases 5. Decline in deaths from hearth disease and stroke 6. Safer and healthier foods 7. Healthier mothers and babies 8. Family planning 9. Fluoridation of drinking water 10. Tobacco as a health hazard www.cdc.gov/about/history/tengpha.htm The value of vaccination “The impact of vaccination on the health of the world’s people is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth” Stanley Plotkin (2013) Vaccine-preventable diseases, by year of vaccine development or licensure. United States,1798-1998. Vaccine Introduction Vaccine Introduction Smallpox 1798 Rubella 1969 Rabies 1885 Antrax 1970 Typhoid 1896 Meningitis 1975 Cholera 1896 Pneumonia 1977 Plague 1897 Adenovirus 1980 Diphtheria 1923 Hepatitis B 1981 Pertussis 1926 H. Influenza B 1985 Tetanus 1927 Japanese encephalitis 1992 Tuberculosis 1927 Hepatitis A 1995
    [Show full text]
  • Piecing Together the HIV Prevention Puzzle AVAC Report 2009 Acknowledgments
    Piecing Together the HIV Prevention Puzzle AVAC Report 2009 Acknowledgments AVAC gratefully acknowledges many friends and colleagues in government, industry, academia and the advocacy community from all over the world for their expertise, guidance and advice as we researched and prepared this Report. AVAC Report 2009 was written and edited by AVAC staff, consultants and board members, and coordinated by Emily Bass. We also want to especially thank Sarah Alexander, Dan Barouch, Linda-Gail Bekker, Seth Berkley, Alan Bernstein, Susan Buchbinder, Gabriela Calazans, Ward Cates, Mark Connors, Larry Corey, Paul de Bakker, Guy de Bruyn, Kevin De Cock, Carl Dieffenbach, Kim Dickson, Jose Esparza, Tim Farley, Patricia Fast, Mark Feinberg, Jorge Flores, David Goldstein, Gregg Gonsalves, Glenda Gray, Yasmin Halima, Cate Hankins, Mark Harrington, Barton Haynes, Sharon Hillier, Peggy Johnston, Richard Klausner, Wayne Koff, Katharine Kripke, Jim Kublin, Dave Levin, Udom Likhitwonnawut, Margaret Liu, Ying Ru Lo, Donna Lomangino, Siobhan Malone, Kay Marshall, Betsy Martin, John Mascola, Bonnie Mathieson, Margaret McCluskey, Elizabeth McGrory, James McIntyre, Natasha Mileshina, Lynn Morris, Kevin O’Reilly, Saladin Osmanov, Myra Ozaeta, Giuseppe Pantaleo, Lynn Paxton, Louis Picker, Frances Priddy, Helen Rees, Robert Reinhard, Supachai Rerks-Ngarm, Mike Robertson, Candace Rosen, Nina Russell, Jerry Sadoff, Jeff Safrit, Allan Schultz, Robin Shattock, Guido Silvestri, Joan Tallada, Jim Tartaglia, Gerald Voss, Sabrina Welsh and Carolyn Williamson. AVAC is dedicated
    [Show full text]
  • Better Global Tools for Influenza
    11–12 June 2019 | Geneva, Switzerland BETTER GLOBAL TOOLS FOR INFLUENZA Technical consultation on product research & innovation for influenza prevention, control & treatment Prevent. Control. Prepare. 11–12 June 2019 | Geneva, Switzerland BETTER GLOBAL TOOLS FOR INFLUENZA Technical consultation on product research & innovation for influenza prevention, control & treatment WHO/WHE/IHM/IPR/2019.1 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Better global tools for influenza. Technical consultation on product research and innovation for influenza prevention, control and treatment, Geneva, Switzerland, 11-12 June 2019.
    [Show full text]
  • Vol. 23, No. 2, 2019
    The Publication on AIDS Vaccine Research WWW.IAVIREPORT.ORG | VOLUME 23, ISSUE 2 | DECEMBER 2019 A new viral vaccine The history of A new efficacy trial of vector has broad vaccination: adapting the mosaic HIV vaccine potential to the times candidate FROM THE EDITOR “It was the best of times, it was the worst of times…” from Janssen Vaccines & Prevention, part of the Jans- So begins Charles Dickens’s famous historical novel A sen Pharmaceutical Companies of Johnson & Johnson, Tale of Two Cities, published in 1859. Dickens was together with a consortium of public partners, began describing the years leading up to the French their second, and largest, efficacy study (named Revolution, yet it is an oddly apt description of the Mosaico) of Janssen’s mosaic-based HIV vaccine candi- current state of the vaccine field. date (see page 16). This October, the first Ebola vaccine was approved by Based on this, one might think it was the best of times. the European Medicines Agency. This is by all accounts But amidst all this progress, global cases of measles are an important milestone in battling outbreaks of a lethal on the rise, a disease for which a highly effective vaccine infectious disease that most often affects people in devel- has been available for more than 50 years. Last year oping countries. This vaccine, known as Ervebo, was more than 140,000 people worldwide died of measles, rapidly developed in 2014 during the deadliest outbreak most of them children under five years old, and 100 mil- of Ebola in history. It is estimated to be 97.5% effective.
    [Show full text]
  • 2008 Annual Progress Report
    International AIDS Vaccine Initiative 2008 Annual Progress Report avi IAVI’s mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. OFFICES New York Headquarters 110 William Street, Floor 27 New York, N..Y. 10038-3901 U.S.A. Tel: +1 212 847 1111 Fax: +1 212 847 1112 East Africa Postal address: P.O. Box 340 KNH Nairobi, Kenya 00202 Tel: +254 20 445 3596/7 Fax: + 254 20 445 3598 Europe Herengracht 208 1016 BS Amsterdam The Netherlands Tel: +31 20 521 0030 Fax: +31 20 521 0039 India D-64, Second Floor, Defence Colony New Delhi, 110 024, India Tel: +91 11 24652668 Fax: +91 11 24646464 Southern Africa Ground Floor, Block 6, Albury Park Corner Albury Road & Jan Smuts Avenue Dunkeld West 2196 Johannesburg, South Africa Tel: +27 11 325 4737 Fax: +27 11 759 6210 www.iavi.org ) [email protected] Copyright © 2009 International AIDS Vaccine Initiative. All rights reserved. International AIDS Vaccine Initiative, IAVI and the IAVI logo are trademarks of the International AIDS Vaccine Initiative, Inc. This report is available online at http://www.iavi.org. Evolution The new AIDS Vaccine The new IAVI Neutralizing A fully operational Design and Development Antibody Center at The Innovation Fund to promote Laboratory Scripps Research Institute cutting-edge science JULIANA THOMAS PHOTOGRAPHY Commitment Global Clinical Community network of trial center outreach and partnerships support social science VANESSA VICK Promise Build scientific and Sustain local, Ensure access to human capacity in national and global vaccines where the developing world focus on ending AIDS they’re needed most VANESSA VICK Message from the President Since we were founded in 1996, the International AIDS Vaccine Initiative has undergone constant change as we have pursued our mission of ensuring the development of an AIDS vaccine for the world.
    [Show full text]
  • Emerging and Reemerging <Italic>Aedes</Italic>-Transmitted Arbovirus Infections in the Region of the Americas: Impli
    AJPH PERSPECTIVES Emerging and Reemerging Aedes-Transmitted Arbovirus Infections in the Region of the Americas: Implications for Health Policy The increasing geographical spread Marcos A. Espinal, MD, DrPH, Jon K. Andrus, MD, Barbara Jauregui, MD, MSc, Stephen Hull Waterman, and disease incidence of arboviral MD, MPH, David Michael Morens, MD, Jose Ignacio Santos, MD, MSc, Olaf Horstick, PhD (DrMed), FFPH, infections are among the greatest MPH, MSc, MBBS, Lorraine Ayana Francis, DrPH, MHA, and Daniel Olson, MD public health concerns in the Americas. The region has observed — an increasing trend in dengue in- he ever-increasing geo- symptomatic infections way ZIKV, like CHIKV, had not Tgraphical spread and rising above the numbers reported to previously circulated within cidence in the last decades, evolv- disease incidence of arboviral PAHO.9 the Western Hemisphere, and ing from low to hyperendemicity. (arthropod-borne virus) in- In 2005, CHIKV caused an resulted in an explosive outbreak Yellow fever incidence has also in- fections are among the most outbreak on the island of in the Americas, with its identi- tensified in this period, expanding significant public health concerns Comoros, followed by a large fication first on Easter Island, from sylvatic-restricted activity in the Americas.1,2 In addition to outbreak in India, resulting in Chile, in 2014, followed by to urban outbreaks. Chikungunya the reemergence of dengue virus more than 1 million cases and northeast Brazil in 2015, and started spreading pandemically in (DENV) and yellow fever virus significant postinfectious mus- then spreading throughout the 2005 at an unprecedented pace, (YFV), new arboviral pathogens culoskeletal sequelae.
    [Show full text]